MACK News and Press, Merrimack Pharmaceuticals Inc. From 05/07/20

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2020 financial results for the period ended March 31, 2020. “We are pleased to report that we have significantly reduced our operating expen...

The opportunity Our previous article highlighted the attractive specialty investment opportunity presented by Merrimack Pharmaceuticals ( MACK ) relative to their regulatory approval-based milestone payments for Onivyde (the liposomal formulation of irinotecan). We will publish follow up...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical nanoliposome programs to Cel...

Overview With the equity markets trading at near record valuations, we’ve been actively looking for mispriced idiosyncratic opportunities, with the hope to find equity -like returns without equity risk. We believe that Merrimack Pharmaceuticals is such an investment. If we are right...

Thinly traded nano cap Merrimack Pharmaceuticals ( MACK +6.1% ) is up on almost 30% higher volume, albeit on turnover of only 66K shares, on the heels of its announcement that it has received a $5M milestone payment from Ipsen S.A. ( OTCPK:IPSEY ) triggered by the latter's decision to ad...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has adopted a Section 382 net operating loss rights plan (the “ Plan ”) and declared a dividen...

Merrimack Pharmaceuticals (NASDAQ: MACK ) declares a special dividend of approx.  $0.50/share . More news on: Merrimack Pharmaceuticals, Inc., Dividend News, , Read more ...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial evaluating ONIVYDE in patients with small-cell lung cancer into the second randomiz...

Small-cap stocks have been weighed down by ongoing uncertainty associated with trade deals and interest rate policy, making it harder than ever to spot potential winners and limit risk. Although small-cap stocks could face headwinds if the economy decelerates, there are specific industries and...

Small-cap stocks have underperformed large-cap stocks, and recent manufacturing and services industry data increases concerns that profits could stagnate. The risk of decelerating economic activity to small-cap stocks shouldn't be ignored, but that doesn't mean there aren't sectors, industries...